Bosutinib, sold under the brand name Bosulif, is a small molecule BCR-ABL and src tyrosine kinase inhibitor used for the treatment of chronic myelogenous...
10 KB (633 words) - 12:29, 5 August 2024
Bosutinib's activity was first described in 2001 and it was disclosed as an Abl kinase inhibitor in 2003. At first it was believed that bosutinib was...
56 KB (6,470 words) - 06:03, 24 October 2024
approved in South Korea for people resistant to or intolerant of imatinib. Bosutinib received US FDA and EU European Medicines Agency approval on 4 September...
34 KB (3,877 words) - 13:44, 25 October 2024
(ALK) Non-receptor bcr-abl Asciminib Bosutinib Dasatinib Imatinib Nilotinib Ponatinib Radotinib Src (Bosutinib Dasatinib) Janus kinase Baricitinib Fedratinib...
12 KB (821 words) - 02:57, 12 October 2024
bornelone (INN) Borofax bortezomib (USAN) Boruzu Bosatria bosentan (INN) bosutinib (USAN, INN) botiacrine (INN) Botox Boudreaux's Butt Paste boxidine (INN)...
7 KB (387 words) - 05:56, 19 October 2024
Sunitinib (Sutent) Dasatinib (Sprycel) Lapatinib (Tykerb) Nilotinib (Tasigna) Bosutinib (Bosulif) Ponatinib (Iclusig) Asciminib (Scemblix) Bortezomib (Velcade)...
20 KB (2,234 words) - 01:21, 22 July 2024
Other tyrosine kinase inhibitor drugs that are in clinical trials include bosutinib, bafetinib, Saracatinib(AZD-0530), XLl-999, KX01 and XL228. HSP90 inhibitor...
21 KB (2,648 words) - 12:12, 26 July 2024
Ixabepilone L01EA01 Imatinib L01EA02 Dasatinib L01EA03 Nilotinib L01EA04 Bosutinib L01EA05 Ponatinib L01EA06 Asciminib L01EB01 Gefitinib L01EB02 Erlotinib...
12 KB (877 words) - 15:36, 25 January 2024
available inhibitors to treat CML are imatinib, dasatinib, nilotinib, bosutinib and ponatinib. Gastrointestinal stromal tumors (GIST) are known to withstand...
43 KB (5,251 words) - 10:44, 24 June 2024
(ALK) Non-receptor bcr-abl Asciminib Bosutinib Dasatinib Imatinib Nilotinib Ponatinib Radotinib Src (Bosutinib Dasatinib) Janus kinase Baricitinib Fedratinib...
12 KB (758 words) - 23:46, 14 March 2024
tyrosine kinase inhibitors (IS-TKIs) (imatinib, nilotinib, dasatinib, or bosutinib). The main efficacy outcome measure was major molecular response rate...
21 KB (1,736 words) - 20:34, 5 November 2024
injectables such as the EpiPen. On September 4, 2012, the FDA approved bosutinib (Bosulif) for chronic myelogenous leukemia (CML), a rare type of leukemia...
168 KB (14,575 words) - 20:40, 12 November 2024
VEGFR1/VEGFR2/VEGFR3/PDGFRB/c-KIT Pfizer Small molecule 2012 Renal cell carcinoma Bosutinib Bcr-Abl / SRC Pfizer Small molecule 2012 Chronic myelogenous leukemia...
23 KB (750 words) - 23:26, 13 August 2024
the LCK tyrosine kinase in cells displaying high level of lipid rafts. Bosutinib Dasatinib Hennequin LF, Allen J, Breed J, Curwen J, Fennell M, Green TP...
7 KB (592 words) - 12:43, 5 August 2024
posterior leucoencephalopathy syndrome (rare) and polycythaemia (uncommon). Bosutinib PO Bcr-Abl and SRc kinase inhibitor. Chronic myeloid leukaemia Diarrhoea...
52 KB (708 words) - 12:37, 26 August 2024
of FIP1L1-PDGFRA. Second generation tyrosine kinase inhibitors, e.g. bosutinib, sorafenib, and nilotinib, show little success in treating T674I FIP1L-PDGFRA...
48 KB (5,760 words) - 10:46, 16 November 2024
the first clinical inhibitor with GI50 of 9–60 nM in cancer cell lines. Bosutinib has been developed for the treatment of chronic myelogenous leukemia by...
3 KB (332 words) - 14:43, 20 November 2023
develop at preclinical and clinical level another drug for CML named bosutinib. He is also the first researcher who (in June 2010) successfully treated...
6 KB (634 words) - 17:22, 22 August 2024
address new, mutated forms of BCR-ABL. These include dasatinib, nilotinib, bosutinib, and ponatinib. Cancer pharmacogenomics has also contributed to the understanding...
36 KB (4,062 words) - 21:54, 14 September 2024